Heparan Sulfate Mimetic Rescue of MSC-Exosome Therapeutic Activity in Senescent Microenvironments

Hypothesis

In aged tissues, senescent cell‑derived exosomes (SCExos) impair the uptake and signaling efficacy of mesenchymal stem cell‑derived exosomes (MSC‑Exos) by downregulating heparan sulfate proteoglycans (HSPGs) on target cells through delivery of oxidized phosphatidylcholine lipids. Restoring HSPG availability with a soluble heparan sulfate mimetic (HSM) will rescue MSC‑Exo-mediated tissue repair despite a senescent‑rich microenvironment.

Mechanistic Rationale

1. SCExo lipid cargo – Senescent cells load exosomes with oxidized phosphatidylcholines (oxPC) that have been shown to bind and internalize HSPGs, leading to their lysosomal degradation (5).
2. HSPG dependence of MSC‑Exo uptake – MSC‑Exos rely on HSPG‑mediated endocytosis for efficient delivery of miRNA cargo (e.g., miR‑19a, miR‑144) to cardiomyocytes and fibroblasts (1).
3. Competitive inhibition – oxPC‑laden SCExos act as molecular decoys, sequestering HSPGs and reducing the surface density available for MSC‑Exo binding, thereby diminishing PI3K/AKT activation and downstream pro‑repair effects.
4. Rescue by HSM – Soluble heparan sulfate mimetics (e.g., PI‑88 or non‑anticoagulant heparin derivatives) can competitively bind oxPC, preventing HSPG depletion and restoring MSC‑Exo entry without affecting coagulation.

Testable Predictions

• In vitro: Co‑culture of human senescent fibroblasts with MSC‑Exos will reduce exosome uptake (measured by fluorescent PKH26 label) by ~40% compared with young fibroblast cultures. Adding HSM at 10 µg/mL will restore uptake to baseline levels.
• Mechanistic read‑out: oxPC levels in SCExos (LC‑MS) will inversely correlate with HSPG expression on recipient cells (flow cytometry). HSM treatment will normalize HSPG surface density.
• Functional outcome: In a murine model of aged myocardial infarction, MSC‑Exo monotherapy will improve ejection fraction by 5 % (ns), whereas MSC‑Exo + HSM will improve ejection fraction by 15 % (p<0.01) and reduce fibrosis (Masson’s trichrome) relative to controls.
• Specificity control: Using HSPG‑deficient fibroblasts (syndecan‑1 knockout) will abolish MSC‑Exo uptake even with HSM, confirming HSPG mediation.

Experimental Design (Outline)

1. Isolation – MSC‑Exos from human bone marrow MSCs (ultracentrifugation + TGF‑β preconditioning); SCExos from irradiated human fibroblasts (senescence confirmed by SA‑β‑gal and p16^INK4a^).
2. Lipid profiling – Quantify oxPC species in SCExos via LC‑MS.
3. Uptake assays – Fluorescent MSC‑Exos added to young vs. senescent fibroblasts ± HSM; flow cytometry and confocal imaging.
4. Signaling – Western blot for p‑AKT, p‑ERK downstream of MSC‑Exo delivery.
5. In vivo – Aged (20‑month) mice subjected to permanent LAD ligation; randomized to PBS, MSC‑Exos, HSM alone, MSC‑Exos+HSM (n=10/group). Echo at baseline, 2 weeks, 4 weeks; histology at endpoint.
6. Statistical analysis – Two‑way ANOVA with post‑hoc Tukey; power analysis targeting 80% power to detect 10 % EF difference.

Falsifiability

If HSM fails to restore MSC‑Exo uptake or functional repair in aged myocardium despite normalizing HSPG levels, the hypothesis is falsified. Conversely, demonstration that HSPG modulation alone (without HSM) rescues efficacy would also challenge the lipid‑decoy mechanism.

Broader Implication

Validating this mechanism would provide a simple adjuvant strategy to overcome the senescence‑induced hostile niche that currently limits exosome therapeutics, directing future clinical trials toward combinatorial regimens that clear or neutralize senescent exosome interference.